Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Market Cap	4.45B -86.4%
Revenue (ttm)	119.28M +223.3%
Net Income	-242.37M
EPS	-0.49
Shares Out	517.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,657,668
Open	8.65
Previous Close	8.55
Day's Range	8.55 - 9.01
52-Week Range	8.01 - 96.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenal ulcer, adult reflux esophagitis, pylori eradication; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer, R+/HER2- locally advanced or metastatic breast cancer, and adjuvant therapy for HR+/HER2- early breast cancer; and XZP-3621, a first-line treatmen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 344
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2575

Financial Performance

In 2025, Xuanzhu Biopharmaceutical's revenue was 51.77 million, an increase of 72.03% compared to the previous year's 30.09 million. Losses were -245.51 million, -55.88% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error